Cpx-351
Burkitt Lymphoma
Children's Hospital Medical Center, CincinnatiPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
74 Active assets in the Burkitt Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Fred Hutchinson Cancer Center | Phase 4 | BBB |
VINCRISTINE SULFATE AIDS Malignancy Consortium | Phase 2 | BBB |
VINDESINE PETHEMA Foundation | Phase 4 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BBB |
Cyclophosphamide AIDS Malignancy Consortium | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Cpx-351 is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →